ANXA5 and B-cell chronic lymphocytic leukemia: The combination of ibrutinib with αhSLAMF6 resulted in a higher percentage of Annexin-V+ cells (Figure 8B and 8C), once again suggesting a synergistic effect of the two agents on human CLL cell survival.